Thrombotic Thrombocytopenic Purpura (TTP) Insights and Trends

• Thrombotic thrombocytopenic purpura (TTP) is caused by a severe deficiency or absence of ADAMTS13 enzyme activity. The disease can occur in either a congenital form, resulting from inherited mutations in the ADAMTS13 gene, or a more common acquired form, which is driven by autoantibodies that inhibit ADAMTS13 activity.
• Analysis of a French national registry found that the rate of TTP in France was 13 cases per million population. Untreated, TTP has a mortality rate of as high as 90%. With plasma exchange, the mortality rate is reduced to 10-20%.
• While severe ADAMTS13 deficiency is central to TTP pathogenesis, it is often insufficient on its own to cause clinical disease. In hereditary TTP, patients may remain asymptomatic until triggering factors such as infection, pregnancy, or inflammation precipitate an acute episode.
• TTP most often occurs after age 40, but congenital forms can occur in children. TTP is more common in women, with a 2:1 female-to-male predominance.
• TTP is a rare disorder with an estimated prevalence of approximately 1 per 100,000 individuals. The disease predominantly affects adults, accounting for nearly 90% of cases, while pediatric-onset TTP represents only about 10% of the patient population. 
• Congenital thrombotic thrombocytopenic purpura (cTTP), caused by inherited mutations in the ADAMTS13 gene, accounts for approximately 3–5% of all TTP cases. Although its exact prevalence remains uncertain, current estimates suggest that cTTP affects approximately 0.5–2 individuals per million population, highlighting its ultra-rare nature.

Thrombotic Thrombocytopenic Purpura (TTP) Epidemiology Forecast in the 7MM

• 2025 Diagnosed Incident Cases of TTP: ~XX
• 2036 Diagnosed Incident Cases of TTP: ~XX
• TTP Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Thrombotic Thrombocytopenic Purpura (TTP) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the GCA, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Thrombotic Thrombocytopenic Purpura (TTP) Understanding 

Thrombotic Thrombocytopenic Purpura (TTP) Overview 

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by severe deficiency of ADAMTS13 activity, resulting in the accumulation of ultra-large von Willebrand factor multimers, platelet aggregation, and widespread microvascular thrombosis. TTP can occur in either an acquired form, driven by autoantibodies against ADAMTS13, or a congenital form caused by inherited mutations in the ADAMTS13 gene. Patients commonly present with thrombocytopenia, microangiopathic hemolytic anemia, neurological manifestations, renal dysfunction, and fever. Current treatment strategies include therapeutic plasma exchange, immunosuppressive therapies such as corticosteroids and rituximab, and targeted agents such as caplacizumab, aimed at controlling acute episodes, preventing relapses, and reducing morbidity and mortality.

Diagnosis of TTP is based on clinical suspicion supported by laboratory evidence of thrombocytopenia and microangiopathic hemolytic anemia. Key diagnostic findings include schistocytes on peripheral blood smear, elevated lactate dehydrogenase levels, reduced haptoglobin, and severe ADAMTS13 deficiency, often accompanied by anti-ADAMTS13 autoantibodies in acquired TTP. Additional laboratory assessments help evaluate organ involvement and exclude other thrombotic microangiopathies. Early and accurate diagnosis is critical, as prompt initiation of therapy can significantly improve outcomes and prevent irreversible organ damage or death.

Further details are provided in the report.

Thrombotic Thrombocytopenic Purpura (TTP) Epidemiology

Key Findings from GCA Epidemiological Analysis and Forecast 

• The United States accounted for approximately 6,000 diagnosed prevalent cases of TTP in 2025, a figure that is expected to increase further by 2036.
• Immune-mediated TTP (iTTP) predominantly affects adults, with pediatric-onset cases accounting for only about 10% of the total patient population. The disease also exhibits a marked female predominance, with women being approximately two to three times more likely to develop iTTP than men.
• Congenital TTP (cTTP), caused by inherited mutations in the ADAMTS13 gene leading to severe ADAMTS13 deficiency, accounts for approximately 3–5% of all TTP cases. Although the exact prevalence remains uncertain, current estimates suggest that cTTP affects approximately 0.5–2 individuals per million population, underscoring its ultra-rare nature.
• According to the French National Thrombotic Microangiopathy (TMA) Registry, childhood-onset immune-mediated TTP (iTTP) is extremely rare, with an estimated annual incidence of approximately 0.2 cases per million population and a prevalence of about 1 case per million.
• There are two main types of TTP – aTTP (the most common) and cTTP (relatively uncommon). In 2025, aTTP and cTTP contributed to 5,500 and 600 diagnosed prevalent cases, respectively.                    

Scope of the Report

• The report covers a segment of a descriptive overview of hand eczema, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

TTP Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting

• 11-year Forecast 

• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of hand eczema? What will be the growth opportunities across the 7MM concerning the patient population with hand eczema?
• What is the historical and forecasted hand eczema patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.